期刊文献+

莫西沙星与左氧氟沙星治疗细菌性感染的细菌学疗效比较的Meta分析 被引量:3

Meta-Analysis on Microbiological Outcomes of Bacterial Infections Treated with Moxifloxacin Versus Levofloxacin
下载PDF
导出
摘要 目的分析比较莫西沙星与左氧氟沙星治疗细菌性感染的细菌学疗效。方法应用RevMan4.2软件对国内2000年至2007年13项莫西沙星和左氧氟沙星治疗细菌性感染的研究进行同质性检验和合并效应量的估计。结果同质性检验χ2=11.05,自由度为10,P=0.35;合并效应量的估计OR合并=2.08,OR合并95%可信限为1.26~3.45;OR合并的检验Z=2.87,P<0.01。结论莫西沙星治疗细菌性感染的细菌学疗效优于左氧氟沙星。 Objective To compare the microbiological outcomes of bacterial infections treated with moxifloxacin versus levofloxacin. MethodsThe microbiological outcomes of 13 studies on bacterial infections treated with moxifloxacin versus levofloxacin were performed the meta- analysis using homogeneity test and combined effect test. Results Homogeneity test showed that the cited studies were homogeneous with: X^2 = 11.05, df= 10 and P =0.35; and by combined effect test, the combined OR was 2. 08 (95% confidence interval = 1.26-3.45, Z = 2.87, P 〈 0. 01). Conclusion The efficacy of moxifloxacin injection on the microbiological outcomes of bacterial infections is better than that of levofloxacin.
出处 《中国药业》 CAS 2009年第15期14-16,共3页 China Pharmaceuticals
关键词 莫西沙星 左氧氟沙星 细菌感染 META分析 moxifloxacin levofloxacin bacterial infections meta - analysis
  • 相关文献

参考文献12

二级参考文献60

  • 1董亮,王树诚,孙恩华,于钦凤,张琦,吴大玮.莫西沙星治疗慢性支气管炎急性加重的临床疗效及体外抗菌活性的研究[J].中国药学杂志,2005,40(9):702-704. 被引量:14
  • 2李仲兴,王秀华,孟晓洁,杨敬芳,时冬艳,王鑫.莫西沙星对224株肠球菌的体外抗菌活性研究[J].中国抗生素杂志,2005,30(7):412-415. 被引量:12
  • 3Rijnders BJ. Moxiflocaxin for Community-Acquired pneumonia[J ].Antimicrob Agents Chemother, 2003,47( 1 ) : 444-5.
  • 4Rodriguez JC, Ruiz M, Lopez M, et al. In vitro activity of moxifloxacin,levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis[J]. Int J Antimicro Agents ,2002,20(6) :464-7.
  • 5Behra-Miellet J ,Dubreuil L,Jumas-Bilak E. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciproflocaxin, clidamycin, metronidazole and beta-lactams[J ]. Int J Antimicrob Agents, 2002,20(5) : 366-74.
  • 6lakovlev VP, Polushkina NR. Moxiflocaxin-antimicrobial activity and pharmacokinetic properties [ J ]. Antibiot Khimioter, 2002, 47 ( 5 ) :19-29. Review.
  • 7Lode H, Garau J. Improving care for patients with respiratory tract infections[J] . J Chemother ,2002,14 ( Suppl 2):22-8.
  • 8BARMAN BALFOUR JA, WISEMAN LR. Moxifloxacin [ J ].Drugs, 1999,57(3) :363-373.
  • 9BARMAN BALFOUR JA, LAMB HM. Moxifloxacin: a reveiew of its clinical potential in the management of community-acquired respiratory tract infections [J ]. Drugs, 2000,59( 1 ) : 115-139.
  • 10TALAN DA. Clinical perspectives on new antimicrobials: focus on fluoroquinolones [J]. Clin Infect Dis,2001,32 Suppl 1 :S64-S71.

共引文献101

同被引文献20

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部